Compare Huntington Ingalls Industries Inc (HII) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs TG Therapeutics Inc — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Huntington Ingalls Industries Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and TG Therapeutics Inc for 16 Days on average.
| HII | TGTX | |
|---|---|---|
Market Cap | $10.44B | $8.16B |
Volume | 440,462 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $453.73 | $59.06 |
52-Week Low | $257.05 | $26.94 |
Typical Hold Time | 28 Days | 16 Days |
Enterprise Value | $13.37B | $8.37B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.51, up 1.47% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a $12.48B revenue, 5.01% net margin, and attractive valuation (P/E 15.78, P/S 0.79). Recent contract wins including a $5.1B aircraft carrier overhaul and 10 unmanned vessel orders provide strong revenue visibility. Analyst consensus is mixed with 40.7% buy ratings but a $363.67 price target suggesting 37% upside potential.
The stock presents value opportunity with strong defense sector positioning and $57.3B backlog, though technical weakness and execution risks on major contracts warrant caution. Upside catalysts include continued earnings beats and contract execution, while risks involve defense budget uncertainty and project delays. Current levels offer entry point for long-term investors given the significant discount to analyst targets.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
